PTU - Polskie Towarzystwo Urologiczne
list of articles:

Infections caused by Enterococcus sp. in urology departments
Article published in Urologia Polska 2005/58/4.


Monika Eliza Strycharczyk 1, Leszek Markuszewski 2, Andrzej Denys 1
1 Zakład Mikrobiologii Lekarskiej i Sanitarnej Katedry Mikrobiologii Uniwersytetu Medycznego w Łodzi
Kierownik zakładu: prof. dr hab. Andrzej Denys
2 Szpital Kliniczny im. WAM, Oddział Kardiologii i Kardiochirurgii, Uniwersytet Medyczny w Łodzi
Dyrektor szpitala: dr n. med. Leszek Markuszewski


urinary tract, Enterococcus sp., urinary tract infections, vancomycin-resistant Enterococcus


Enterococci are often responsible for causing hospital infections including urinary tract infections. They naturally colonize lower intestinal tract, oral cavity and genitourinary tract. It is suggested that the most nosocomial infections are caused by bacteria producing biofilm, which enable them surviving in urinary tract and avoiding immunological response of the host. The main pathogenicity factors of enterococci are: cytolisine, aggregation substance, gelatinase, surface protein Esp. The hospital environment may play an important role in transmission of infections. Epidemiological data have suggested that spreading of enterococci takes place by hands, clothes of medical service workers and medical equipment surfaces, where bacteria can survive very long. Enterococci are most often isolated from urinary tract infection cases of which 14.6% cases were polymicrobial. These bacteria cause about 15% infections in chronic cathetered patients. A shorter time of catheterization may reduce frequency of bacteriuria and necessity of using antibiotics. An emerging vancomycin-resistant enterococcal isolates and increasing level resistance to peniciline and aminoglycosides considerably limits therapeutical options. So, the prevention of vancomycin-resistant Enterococcus (VRE) colonisation and infection should be very important for clinicians because of decreasing patients' mortality, counteracting resistance emerging among S. aureus and decreasing health care costs.


  1. Moore KN, Day RA, Albers M: Pathogenesis of urinary tract infections: a review. J Clin Nursing 2002, 11, 568-574.
  2. Gordon S, Swenson JM, Hill BC et al: Antimicrobial susceptibility patterns of common and unsual species of enterococci causing infections in the United States. J Clin Microbiol 1992, 30, 2373-2378.
  3. Uehling DT, Hahnfeld LE, Scanlan KA: Urinary tract abnormalities in children bacterial nephritis. BJU Int 2000, 85, 885-888.
  4. Tsuchimori N, Hayashi R, Shino A et al: Enterococcus faecalis aggravates pyelonephritis caused by Pseudomonas. aeruginosa in experimental ascending mixed urinary tract infection in mice. Infect Immun 1994, 62, 4534-4541.
  5. Jett B, Huycke MM, Gilmore MS: Virulence of enterococci. Clin Microbiol Rev 1994, 7, 462-478.
  6. Shankar N, Lockatell V, Baghdayan AS et al: Role of Enterococcus faecalis surface protein Esp in the pathogenesis of ascending urinary tract infection. Infect Immun 2001, 69, 4366-4372.
  7. Vankerckhoven V, Van Autgaerden T, Vael C et al: Development of a Multiplex PCR for the Detection of asa1, gelE, cylA, esp, and hyl Genes in Enterococci and Survey for Virulence Determinants among European Hospital Isolates of Enterococcus faecium. J Clin Microbiol 2004, 42, 4473-4479.
  8. Joyanes P, Pascual A, Martinez-Martinez L et al: In vitro adherence of Enterococcus faecalis and Enterococcus faecium to plastic biomaterials. Clin Microbiol Infect 1999, 5, 382-386.
  9. Kreft B, Marre R, Schramm U, Wirth R: Aggregation substance of Enterococcus faecalis mediates adhesion to cultured renal tubular cells. Infect Immun 1992, 60, 25-30.
  10. Tomita H, Ike Y: Tissue-specific adherent Enterococcus faecalis strains that show highly efficient adhesion to Human Bladder Carcinoma T24 cells also adhere to extracellular matrix proteins. Infect Immun 2004, 72, 5877-5885.
  11. Looke D: Vancomycin-resistant enterococci. Nephrology 2002, 7, S67-S68.
  12. Neely AN, Maley MP: Survival of enterococci and staphylococci on hospital fabrics and plastic. J Clin Microbiol 2000, 38, 724-726.
  13. Mascini EM, Bonten MJM: Vancomycin-resistant enterococci: consequences for therapy and infection control. Clin Microbiol Infect 2005, 11 (Suppl. 4), 43-56.
  14. Donskey CJ, Chowdhry TK, Hecker MT et al: Effect of antibiotic therapy on the density of vancomycin-resistant enterococci in the stool of colonized patients. N Engl J Med 2000, 343, 1925-1932.
  15. Rokosz A, Sawicka-Grzelak A, Serafin I, Łuczak M: Szpitalne i pozaszpitalne mieszane zakażenia układu moczowego. Przegl Urolog 2003, 6, 34-39.
  16. Schlager TA, Hendley JO, Wilson RA et al: Correlation of periuretheral bacterial flora with bacteriuria and urinary tract infection in children with neurogenic bladder receiving intermittent catheterization. J Infect Dis 1999, 28, 346-350.
  17. Zhanel GG, Laing NM, Nichol KA et al: Antibiotic activity against urinary tract infection (UTI) isolates of vancomycin-resistant enterococci (VRE): results from the 2002 North American Vancomycin Resistant Enterococci Susceptibility Study (NAVRESS). J Antimicrob Chemother 2003, 52, 382-388.
  18. Giedrys-Kalemba S, Jursa J, Mączyńska I: Zakażenia dróg moczowych na oddziałach urologicznych. Przegl Urolog 2003, 2, 42-48.
  19. Maraha B, Bonten H, van Hooff H et al: Infectious complications and antibiotic use in renal transplant recipients during a 1-year follow-up. Clin Microbiol Infect 2001, 7, 619-625.
  20. Kehinde EO, Rotimi VO, Al. -Hayan A et al: Bacteriology of urinary tract infection associated with indwelling J ureteral stents. J Endourol 2004, 18, 891-896.
  21. Bouza E, San Juan R, Mun˜oz P et al: A European perspective on nosocomial urinary tract infections I. Report on the microbiology workload, etiology and antimicrobial susceptibility (ESGNI_003 study). Clin Microbiol Infect 2001, 7, 523-531.
  22. Naber KG: Racjonalne stosowanie antybiotyków w leczeniu szpitalnych zakażeń układu moczowego. Zakażenia 2003, 4, 29-30.
  23. Chuang P, Parikh CR, Langone A: Urinary tract infections after renal transplantation: a retrospective review at two US transplant centers. Clin Transplant 2005, 19, 230-235.
  24. Kau AL, Martin SM, Lyon W et al: Enterococcus faecalis tropism for the kidneys in the urinary tract of C57BL/6J mice. Infect Immun 2005, 73, 2461-2468.
  25. Min YH, Leong JH, Choi YJ et al: Heterogenity of macrolide, lincosamide-streptogramin resistance phenotypes in enterococci. Antimicrob Agents Chemother 2003, 47, 3415-3420.
  26. Serafin I, Rokosz A, Sawicka-Grzelak A, Łuczak M: Identyfikacja i lekowrażliwość uropatogennych bakterii Gram (+). Przegl Urolog 2004, 5, 10-14.
  27. Cetinkaya Y, Falk P, Mayhall CG: Vancomycin-resistant enterococci. Clin Microb Rev 2000, 13, 686-707.
  28. Michalska K, Tyski S: Charakterystyka oksazolidynonów. Mikrobiol Med 2004, 38, 19-23.
  29. Chang S, Sievert DM, Hageman JC et al: Infection with vancomycin-resistant Staphylococcus aureus containing the vanA gene. N Engl J Med 2003, 348, 1342-1347.
  30. Willems RJL, Homan W, Top J et al: Variant esp gene as a marker of a distinct genetic lineage of vancomycin resistant Enterococcus faecium spreading in hospitals. Lancet 2001, 357, 853-855.
  31. Jursa J, Giedrys-Kalemba S: Skuteczność antybiotykoterapii w zakażeniach dróg moczowych na oddziałach urologicznych ? wybrane aspekty. Zakażenia 2004, 2, 39-45.
  32. Segreti J: Efficacy of current agents used in the treatment of Gram-positive infections and the consequences of resistance. Clin Microbiol Infect 2005, 11, Suppl. 3, 29-35.
  33. Mészáros J, Rokosz A: Chemioterapia zakażeń układu moczowego. Przegl Urol 2001, 2, 18-20.
  34. Naber KG: Racjonalne stosowanie antybiotyków w leczeniu szpitalnych zakażeń układu moczowego. Zakażenia 2003, 8, 29-30.
  35. Mehr SS, Powell CVE, Curtis N: Cephalosporin resistant urinary tract infections in young children. J Paediatr Child Health 2004, 40, 48-52.
  36. Zhanel GG, Karlovsky JA, Harding GKM et al: A Canadian national surveillance study of urinary tract isolates from outpatients: Comparison of the actievities of trimetoprim-sulfametoxazole, ampicilin, mecillinam, nitrofurantoin and ciprofloxacin. Antimicrob Agents Chemother 2000, 44, 1089-1092.
  37. Kamińska W: Zakażenie układu moczowego u kobiet. Zakażenia 2004, 5, 24-31.
  38. Atta MG, Eustace JA, Song X et al: Outpatient vancomycin use and vancomycin-resistant enterococcal colonisation in maintenance dialysis patients. Kidney Int 2001, 59, 718-724.
  39. Vergis EN, Hayden MK, Chow JW et al: Determinants of vancomycin resistance and mortality rates in enterococcal bacteremia. Ann Intern Med 2001, 135, 484-492.
  40. Brauers J, Kresken M, Hafner D, Shah PM: Surveillance of linezolid resistance in Germany, 2001-2002. Clin Microbiol Infect 2005, 11, 39-46.
  41. Chang S, Sievert DM, Hageman JC et al: Inhibitory and bactericidal effects of telithromycin (HMR 3647, RU 56647) and five comparative antibiotics, used singly and in combination, against vancomycin-resistant and vancomycin-susceptible enterococci. Chemotherapy 2001, 47, 250-60.
  42. Gales AC, Sader HS, Jones RN: Antimicrobial activity of dalbavancin tested against Gram-positive clinical isolates from Latin American medical centres. Clin Microbiol Infect 2005, 11, 95-100.
  43. Cha R, Grucz Jr RG, Rybak MJ: Daptomycin dose-effect relationship against resistant Gram-positive organisms. Antimicrob Agents Chemother 2003, 47, 1598-1603.
  44. Alder J, Li T, Yu D et al: Analysis of Daptomycin Efficacy and Breakpoint Standards in a Murine Model of Enterococcus faecalis and Enterococcus faecium Renal Infection. Antimicrob Agents Chemoth 2003, 47, 3561-3566.
  45. Mercier RC, Kennedy C, Meadows C: Antimicrobial activity of tigecycline (GAR-936) against Enterococcus faecium and Staphylococcus aureus used alone and in combination. Pharmacotherapy 2002, 22, 1517-23.


Monika Eliza Strycharczyk
Zakład Mikrobiologii Lekarskiej i Sanitarnej
plac Hallera 1
90-647 Łódź
tel. 042 633 84 66